2026-10-08 · Center for Medicine in the Public Interest
The Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
with Peter Pitts, President — Center for Medicine in the Public Interest

The rising popularity of GLP-1 medications for weight loss has been accompanied by dangers in the gray market, including counterfeit and unapproved drugs, says Peter Pitts, president of the Center for Medicine in the Public Interest, in a Health Policy Podcast interview with Bryan Hyde. Pitts discusses the health implications of using these drugs without medical supervision and the risks associated with counterfeit and unapproved medications. He emphasizes the importance of FDA oversight and urges consumers to consult healthcare professionals before seeking weight loss solutions online.
Related coverage
The Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
In a recent episode of the Health Policy Podcast, Peter Pitts, President of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, discussed the growing popularity of GLP-1 medications for weight loss and the dangers associated with their misuse. Pitts highlighted the implications of obesity in the United States and the risks posed by unregulated sources of these medications.
Obesity rates in the U.S. have reached alarming levels, prompting a search for effective solutions. Pitts emphasized that weight management should not be viewed solely as a cosmetic issue but as a crucial factor in reducing health risks and healthcare costs. "Being the proper weight is a really important thing to make sure we live longer, healthier lives," he said.
Historically, weight loss strategies have focused on diet and exercise, but many people struggle to maintain these lifestyle changes. The emergence of GLP-1 medications, which can promote weight loss, has created a "magic pill" mentality. Pitts warned that these drugs are not intended for long-term use and should be combined with lifestyle changes. He noted that patients often ignore this guidance, seeking a quick fix without altering their habits.
The rise of the gray market for GLP-1s poses significant risks. Pitts pointed out that many individuals turn to unregulated online sources to obtain these medications, often out of embarrassment or frustration with their healthcare providers. "People are willing to sell you anything for any price if you're willing to put rationale and reason aside," he said. This trend has led to the proliferation of counterfeit and unapproved drugs, which can have dangerous health consequences.
Pitts explained that counterfeit drugs may contain misleading labels and could be entirely ineffective or even harmful. "The impact could have— it has no impact at all. The impact could be you get a serious healthcare consequence because of poor manufacturing quality," he said. He emphasized the importance of obtaining medications through legitimate channels to mitigate these risks.
The dangers of using unregulated GLP-1s extend beyond ineffective weight loss. Pitts noted that individuals could experience serious health issues, including hospitalizations or even death, from using these products. He urged consumers to recognize that the pursuit of a bargain can lead to costly health consequences.
Pitts also addressed the regulatory landscape, asserting that the FDA remains the gold standard for drug approval and safety. He acknowledged that while the FDA's processes can be time-consuming and expensive, they are essential for ensuring the safety and efficacy of medications. "The public has the authoritative voice of an FDA-approved product," he said.
Despite the FDA's efforts to combat illegal drug sales, Pitts expressed concern that these measures have not been sufficiently effective. He called for closer collaboration between the FDA and law enforcement agencies to prosecute those involved in selling unapproved medications.
For individuals seeking legitimate weight loss solutions, Pitts offered several recommendations. He advised consumers to utilize official manufacturer websites, such as those for Eli Lilly and Novo Nordisk, which provide affordable options for GLP-1 medications. He also cautioned against offers that seem too good to be true and encouraged open communication with healthcare providers.
Pitts concluded by emphasizing the importance of understanding the regulatory process and maintaining a healthy skepticism toward unverified online offers. He stated, "Sometimes a bargain is just too expensive."
The discussion underscored the complexities surrounding the use of GLP-1 medications for weight loss and the potential dangers of the gray market. As the obesity crisis continues to affect millions of Americans, the need for informed decision-making and adherence to medical guidance remains paramount.
Interview Q&A
Q&A: The Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
The Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
Q: Can you provide some background about yourself?
A: I am Peter Pitts, President of the Center for Medicine in the Public Interest and a former FDA Associate Commissioner.
Q: What is the current issue with GLP-1s in relation to obesity?
A: The issue is that obesity is a significant problem in the U.S., and while GLP-1s can aid in weight loss, they are not intended for long-term use. They should be combined with lifestyle changes, but many people ignore this guidance.
Q: Why are some people turning to unregulated sources for GLP-1s?
A: People may feel embarrassed to discuss weight loss with their doctors, especially if their doctors recommend lifestyle changes instead of medication. This leads them to seek out unregulated sources online.
Q: What are the dangers of purchasing GLP-1s from illegitimate suppliers?
A: There are two main dangers: counterfeit drugs that are misrepresented and unapproved drugs that lack FDA oversight. These can lead to serious health risks, including hospitalization or worse.
Q: Can you elaborate on the potential health consequences of using unapproved GLP-1s?
A: Using unapproved products can result in negative health outcomes due to poor manufacturing quality or unknown ingredients. There is also no legal recourse if something goes wrong.
Q: Are there any legitimate breakthroughs in weight loss treatments?
A: While there is data supporting the effectiveness of GLP-1s, we lack long-term data on their chronic use. It is essential to conduct thorough studies before making assumptions about their safety and efficacy.
Q: What is your opinion on the FDA's approval process?
A: The FDA's process is thorough and ensures that drugs are safe and effective. While it can be time-consuming and costly, it provides the public with confidence in approved products.
Q: Is there a regulatory body that compares to the FDA globally?
A: The FDA is considered the gold standard for regulatory review, and many countries base their approval processes on the FDA's standards.
Q: What steps can the FDA take to improve its processes?
A: The FDA could benefit from additional staffing and funding to expedite the review process. It also needs to enhance efforts to shut down illegal drug operations.
Q: What are some rules of thumb for consumers to avoid unsafe products?
A: First, check legitimate manufacturer websites for affordable options. Second, be wary of deals that seem too good to be true. Lastly, do not hesitate to discuss concerns with your doctor.
Q: How can consumers maintain a healthy skepticism regarding online offers?
A: It is essential to apply common sense and recognize that effective weight management requires lifestyle changes, not just reliance on pills.
Q: What does the Center for Medicine in the Public Interest do?
A: The Center for Medicine in the Public Interest promotes smart regulatory policy to encourage innovation and improve public understanding of the FDA and drug development processes.
Q: Where can people find more information about your organization?
A: Our website is www.cmpi.org, where you can learn more about our initiatives and resources.
Key questions
What are GLP-1s and why are they becoming popular for weight loss?
GLP-1s are medications that help with weight loss by regulating appetite and insulin levels. They have gained popularity due to the obesity crisis and the desire for effective weight management solutions.
What are the risks of using GLP-1s without medical supervision?
Using GLP-1s without medical supervision can lead to serious health consequences, including adverse reactions from counterfeit or unapproved drugs, and potential long-term health risks due to lack of clinical data on chronic use.
How can consumers identify legitimate GLP-1 products?
Consumers should look for FDA-approved products and avoid purchasing from questionable online sources. It's advisable to consult a healthcare provider for prescriptions and guidance.
What are the dangers of the gray market for GLP-1s?
The gray market poses risks such as counterfeit drugs, lack of quality control, and the potential for harmful substances in unregulated products, which can lead to serious health issues.
What steps is the FDA taking to address illegal sales of GLP-1s?
The FDA has issued warnings to companies selling illegal GLP-1s and is working to collaborate with law enforcement to prosecute those involved in these illegal activities.
What advice does Peter Pitts give for those considering GLP-1s?
Pitts advises individuals to prioritize consulting their doctor, consider the risks of unregulated products, and focus on lifestyle changes such as diet and exercise instead of seeking a 'magic pill.'
How can people avoid being scammed when looking for weight loss medications?
People should be cautious of offers that seem too good to be true, seek out legitimate sources like manufacturer websites, and not hesitate to discuss their concerns with their healthcare provider.
Key takeaways
- “Being the proper weight is a really important thing to make sure we live longer, healthier lives.”
- “GLP-1s are indicated to be used in combination with diet and exercise.”
- “The most important consequence is unintended, very negative health consequences for the people that are trying to circumvent the system.”
- “Buyer beware. Caveat emptor, you know, is bad pharmaceutical policy.”
- “Sometimes a bargain is just too expensive, as my grandmother used to say.”
- “If something looks too good to be true, a big red flag should go up.”
About the guest
President — Center for Medicine in the Public Interest
Peter Pitts is president of the Center for Medicine in the Public Interest.
Full transcript
Show full transcriptHide transcript
Filed under
